XORTX Therapeutics Company Insiders
| XRTX Stock | USD 1.27 0.06 4.96% |
XORTX Therapeutics employs about 2 people. The company is managed by 7 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 0.29 employees per reported executive. Break down of XORTX Therapeutics' management performance can provide insight into the company performance.
XORTX |
XORTX Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2936) %, meaning that it created substantial loss on money invested by shareholders. XORTX Therapeutics' management efficiency ratios could be used to measure how well XORTX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to rise to -0.89 in 2024. At this time, XORTX Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 189 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.Common Stock Shares Outstanding is likely to rise to about 2.1 M in 2024, despite the fact that Net Loss is likely to grow to (8.1 M).
XORTX Therapeutics Workforce Comparison
XORTX Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 90.0. XORTX Therapeutics holds roughly 2.0 in number of employees claiming about 2.22% of equities under Health Care industry.
XORTX Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. XORTX Therapeutics Price Series Summation is a cross summation of XORTX Therapeutics price series and its benchmark/peer.
XORTX Therapeutics Notable Stakeholders
A XORTX Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as XORTX Therapeutics often face trade-offs trying to please all of them. XORTX Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting XORTX Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David MBA | Director Development | Profile | |
| MD MBA | Chief Officer | Profile | |
| Charlotte May | Corporate Secretary | Profile | |
| MRCP MD | Chief Officer | Profile | |
| David MacDonald | Consultant Operations | Profile | |
| Nick Rigopoulos | Director Communications | Profile | |
| Allen Davidoff | CEO, Founder | Profile |
About XORTX Therapeutics Management Performance
The success or failure of an entity such as XORTX Therapeutics often depends on how effective the management is. XORTX Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XORTX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XORTX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.94) | (0.89) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.47) | (0.49) |
Please note, the imprecision that can be found in XORTX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XORTX Therapeutics. Check XORTX Therapeutics' Beneish M Score to see the likelihood of XORTX Therapeutics' management manipulating its earnings.
XORTX Therapeutics Workforce Analysis
Traditionally, organizations such as XORTX Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare XORTX Therapeutics within its industry.XORTX Therapeutics Manpower Efficiency
Return on XORTX Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 308.3K | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 539.1K |
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.